Literature DB >> 11883252

[Three dimensional sonography in nuchal translucency measurements between 10th and 14th weeks of gestation].

A Czekierdowski1, G Chołubek, K Sodowski, J Kotarski.   

Abstract

Our objective was to determine the practical usefulness of 3D transvaginal sonography in nuchal translucency (NT) measurements between 10th and 14th week of gestation. Thirty-six women (18 primiparas) were studied with the use of Kretz Voluson 530 and 730 scanners (Kretztechnik, Zipf, Austria). Two different volume scans were performed in all subjects according to the new 4 steps method proposed by Chung et al (2000). Nuchal translucency of the first and second scan were compared. In all but one (2.7%) cases good quality images were obtained. Mean value of NT of the first and second scan were 1.463 +/- 0.551 mm (SD) and 1.475 +/- 0.556 mm (SD), respectively. The differences as compared by two tailed t-test for paired measurements were not significant (p = 0.668). There was a significant correlation between first and second measurement (r = 0.96), also the interoperator variability was good. Our preliminary study indicates that 3D sonography is a useful tool in nuchal translucency measurements at the end of the first trimester of pregnancy. The results, however, need to be prospectively tested in larger population.

Entities:  

Mesh:

Year:  2001        PMID: 11883252

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  2 in total

1.  Evaluation of mitral valve prolapse using newly developed real-time three-dimensional echocardiographic system with real-time volume rendering.

Authors:  Omer Goktekin; Makoto Matsumura; Ryozo Omoto; Shunei Kyo; Tsuyoshi Mochizuki
Journal:  Int J Cardiovasc Imaging       Date:  2003-02       Impact factor: 2.357

Review 2.  Three- and 4-dimensional ultrasound in obstetric practice: does it help?

Authors:  Luís F Gonçalves; Wesley Lee; Jimmy Espinoza; Roberto Romero
Journal:  J Ultrasound Med       Date:  2005-12       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.